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The fact that mortality rates in many cancers have fallen
only slowly since the declaration of the ‘war on cancer’ in
1971 (Espey et al. 2007) suggests that novel approaches to
both therapy and prevention are required. Two such
efforts were launched this year. In February, the National
Cancer Institute sponsored a meeting titled, ‘Integrating
and Leveraging the Physical Sciences to Open a New
Frontier in Oncology’, based on the premise that, ‘Cancer
research needs new ideas, deep innovation, and new and
unprecedented transdisciplinary teams of scientists…’.
Independently, a working group of cancer biologists, evo-
lutionary biologists, systems and computational biologists,
and physicians convened in May at the Santa Fe Institute
(SFI) with similar goals (Pepper 2008b). In both cases,
consensus emerged that somatic (within-body) cellular
selection and evolution is the fundamental process by
which neoplasms arise, acquire malignancy, and evade
therapeutic interventions (Frank and Nowak 2004; Crespi
and Summers 2005; Maley and Reid 2005; Merlo et al.
2006). This hypothesis was introduced in the 1970s
(Cairns 1975; Nowell 1976), and has since garnered
enough empirical support to rise to the level of a scien-
tiﬁc theory, which, ‘explains various large and indepen-
dent classes of facts’ (Polyak 2007, p. 107).
The emerging interest in somatic evolution in cancer
biology is timely. New technologies are providing
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Abstract
There is increasing evidence that Darwin’s theory of evolution by natural selec-
tion provides insights into the etiology and treatment of cancer. On a micro-
scopic scale, neoplastic cells meet the conditions for evolution by Darwinian
selection: cell reproduction with heritable variability that affects cell survival
and replication. This suggests that, like other areas of biological and biomedical
research, Darwinian theory can provide a general framework for understanding
many aspects of cancer, including problems of great clinical importance. With
the availability of raw molecular data increasing rapidly, this theory may pro-
vide guidance in translating data into understanding and progress. Several con-
ceptual and analytical tools from evolutionary biology can be applied to cancer
biology. Two clinical problems may beneﬁt most from the application of Dar-
winian theory: neoplastic progression and acquired therapeutic resistance. The
Darwinian theory of cancer has especially profound implications for drug
development, both in terms of explaining past difﬁculties, and pointing the
way toward new approaches. Because cancer involves complex evolutionary
processes, research should incorporate both tractable (simpliﬁed) experimental
systems, and also longitudinal observational studies of the evolutionary dynam-
ics of cancer in laboratory animals and in human patients. Cancer biology will
require new tools to control the evolution of neoplastic cells.
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of cancer, data that can be used to test Darwinian theo-
ries of cancer progression and therapeutic response by
employing both a well-developed body of theory and an
armamentarium of analytical tools from evolutionary
biology. Here, we review some of these tools, and how
they can be applied to basic problems in cancer biology.
Although the role of somatic evolution in cancer is rarely
disputed, it has seldom been integrated into biomedical
research. We begin by discussing how tools from evolu-
tionary theory may be applied to cancer biology. We
examine two key clinical challenges as opportunities for
the integration of evolutionary biology into cancer biol-
ogy: predicting progression to malignancy and preventing
acquired therapeutic resistance. We also consider the
implications of the somatic evolution theory of cancer for
drug development. Finally, we discuss how research into
cancer stem cells may be integrated into the evolutionary
theory of cancer.
Importing tools from evolutionary biology into
cancer biology
The mathematical theory of Darwinian dynamics provides
tools for understanding and predicting responses to
somatic selection, including clonal adaptation, diversiﬁca-
tion and extinction (Vincent and Brown 2005). This
framework has been used to develop explanatory models
of cancer initiation, promotion and progression (Michor
et al. 2004; Vincent and Gatenby 2008). Consideration of
cellular evolutionary dynamics can also guide develop-
ment of novel therapeutic strategies (Maley et al. 2004c).
Techniques originally developed to reconstruct the evo-
lutionary history of species have since been applied to trac-
ing the somatic lineages of normal and cancer cells within
an individual (Frumkin et al. 2008; Shibata 2008). In
organismal biology, such phylogenetic reconstruction
permits the comparative analysis of adaptation through
methods such as independent contrasts (Felsenstein 1985).
Similar comparative analysis of cancer cell phylogenies
could reveal which molecular changes occurring during
neoplastic progression facilitate the development of
invasive, metastatic and resistant cell phenotypes.
Two further developments in evolutionary theory may
also be applicable. The ﬁrst results from renewed interest
in the evolutionary genetics of adaptation (Orr 2005)
which suggests that just a few mutations are typically
involved in conferring the bulk of adaptive evolution in
mutation-limited populations such as cancer cells. This
theory may be particularly relevant in predicting the
progression of cancers following treatment failure, as it
suggests that compensatory evolution (the recovery of ﬁt-
ness losses due to the acquisition of costly resistance
mutations) may occur extremely fast. There is even
evidence that many resistance mutations may not be
costly in the ﬁrst place (Shah et al. 2007), a phenomenon
that is also seen in bacteria (Kassen and Bataillon 2006).
A second applicable advance in evolutionary biology is
the development of theory for ‘multilevel selection’, or nat-
ural selection at multiple levels of biological organization
(Keller 1999; Okasha 2006). Somatic selection occurs solely
at the level of the cell. However, for understanding human
defenses against and vulnerability to cancer, the history of
selection among individuals due to cancer is also important
(Leroi et al. 2003; Greaves 2007). It is also useful to con-
sider how these two levels of selection have interacted and
shaped each other. For example, individual selection has
apparently shaped patterns of ongoing somatic cell differ-
entiation that suppress somatic selection (Pepper et al.
2007). Efforts at cancer prevention may beneﬁt from the
study of the mechanisms that evolution has discovered for
suppressing cancer in various organisms (Leroi et al. 2003).
Conceptual contributions to cancer biology from
organismal biology have derived from the consideration
of ecological (e.g. competition, predation) as well as evo-
lutionary processes (Merlo et al. 2006). One novel appli-
cation is the use of engineered bacteria as competitors
and predators of cancer cells in the hypoxic environments
they create inside tumors, where other agents lose effec-
tiveness (Dang et al. 2001). Another possibility involves
the use of oncolytic viruses as predators (Davis and Fang
2005), and speaks to the nature of the therapeutic agents
themselves. As pointed out by Levin and Bull (Levin and
Bull 2004) in the context of treatment of bacterial dis-
eases, phage have one outstanding advantage over con-
ventional antibiotics: a phage population can itself evolve
to overcome bacterial resistance whereas antibiotics – and
both conventional and targeted cancer chemotherapies –
are evolutionarily inert; once drug resistance evolves, the
therapy fails. By contrast, oncolytic viruses are, at least in
principle, capable of evolving rapidly. The potential there-
fore exists for using selection to evolve oncolytic viruses
with desirable attributes such as attenuated (or enhanced)
virulence or increased tumor cell tropism. Of course, this
evolvability is a double-edged sword, for it also opens up
the possibility of genetic adaptation of the therapeutic to
nontarget tissues, i.e. evolution of a pathogenic virus.
Early results suggest, however, that at least for some can-
didate oncolytic viruses (e.g. poliovirus employed to treat
glioblastoma multiforme), evolution of pathogenicity does
not occur (Dobrikova et al. 2008). Moreover, in at least
one model system, persistent infection by oncolytic reovi-
rus dramatically impedes tumor development, and
although infected cells subsequently cleared of reovirus
are tumorigenic, they have not acquired resistance to the
virus (Alain et al. 2006).
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adopted only to the extent that they translate into clear
directions for clinical advances. The two clinical chal-
lenges where we seem likely to beneﬁt most directly from
adopting the perspective of somatic evolution are predict-
ing progression to malignancy and preventing acquired
therapeutic resistance.
Neoplastic progression
Not all premalignant neoplasms progress to cancer. It is
therefore important to identify risk factors for progression
as early as possible because, in many cancers, early detec-
tion and intervention improve survival (Etzioni et al.
2003). Moreover, the risks, hardship and expense of inter-
vention can be minimized by recognizing when interven-
tion is unnecessary. Predictors of progression to cancer
that are independent of particular genes or tumor types –
and hence, may be generic indicators of cancer risk –
include genetic instability (Maley et al. 2004a; Galipeau
et al. 2007) and genetic diversity (Maley et al. 2006; Heng
2007), as well as signatures of ongoing somatic evolution
such as clonal expansion (Maley et al. 2004b; Heng 2007).
Monitoring these attributes of cell populations may allow
us to tailor interventions to the current level of risk
(Galipeau et al. 2007).
Because neoplastic progression is a process of somatic
evolution, reducing evolutionary rates should decrease can-
cer incidence. Evolutionary theory suggests that this could
be accomplished by reducing the mutation rate, reducing
the effective population size of cells, increasing the genera-
tion time of the self-renewing cells (e.g. through cytostatic
agents or agents capable of inducing cell-cycle arrest or
senescence), or reducing the relative ﬁtness of carcinogenic
mutations. Unfortunately, we currently lack tools to mea-
sure those attributes of neoplasms, let alone manipulate
them. One possibility is to reduce the mutation rate via
therapeutic reduction in mutagen exposure. For example,
nonsteroidal anti-inﬂammatory drugs, such as aspirin, are
associated with as much as a ﬁvefold reduction of risk of
progression in Barrett’s esophagus (Corley et al. 2003;
Vaughan et al. 2005). This may be due to a reduction in
mutagens in the form of oxygen radicals produced during
inﬂammation. Suppressing inﬂammation may also remove
proliferative signals normally involved in wound healing,
and so may prolong the cell cycle of neoplastic cells and
reduce the number of multiplying tissue stem cells, thereby
reducing evolutionary rates.
Acquired drug resistance
Acquired drug resistance is a major problem in the treat-
ment of most cancers (Moscow et al. 2003; O’Connor
et al. 2007). In the clinic, patients often respond to the
initial application of a therapy but are prone to relapse,
at which point repeating the same therapy is rarely effec-
tive. The situation is even more dire for patients present-
ing with metastatic cancers, where initial response to
therapy is undermined by subsequent disease progression.
In both instances, it is clear that therapeutic sensitivity of
the tumor has declined over the course of treatment.
Decades ago, Nowell postulated that the emergence of
drug resistance in cancer was driven by somatic evolution
(Nowell 1976), a hypothesis for which there is now sub-
stantial empirical support. For example, early work found
methotrexate (a common chemotherapy employed for
many different cancers) resistance due to ampliﬁcation
(extra copies) of its target gene, dihydrofolate reductase
(DHFR), in clinical samples after methotrexate therapy
(Curt et al. 1983; Carman et al. 1984; Horns et al. 1984;
Trent et al. 1984). Similarly, 5-ﬂurouracil – another com-
mon chemotherapy – selects for ampliﬁcation in its target
gene, thymidylate synthase (TYMS), causing acquired
therapeutic resistance (Wang et al. 2004). Some of the
most compelling evidence comes from chronic myeloid
leukemia, where longitudinal blood samples have revealed
the acquisition of a series of mutations in the gene BCR-
ABL, inducing resistance to sequential ABL kinase inhibi-
tor therapies (imatinib and dasatinib) (Shah et al. 2007).
Similarly, geﬁtnib selects for mutations in its target gene,
epidermal growth factor receptor (EGFR) (Kobayashi
et al. 2005). However, ampliﬁcation of a downstream
gene, MET, can also induce acquired resistance to geﬁti-
nib (Engelman et al. 2007). Anti-androgen therapies in
prostate cancer select for mutations that cause hypersensi-
tivity in the androgen receptor (AR) (Taplin et al. 1999)
as well as ampliﬁcation of that gene (Visakorpi et al.
1995). Consistent with the idea that therapies impose new
selective pressures, a recent, genetic comparison of pre-
therapy and relapse samples in acute lymphoblastic leuke-
mia found that the clone detected at relapse was often
present as a minority clone prior to therapy (Mullighan
et al. 2008).
If acquired therapeutic resistance reﬂects largely a Dar-
winian dynamic, then the key will be to design therapeu-
tic interventions that both reduce tumor burden and
delay or prevent the evolution of therapeutic resistance.
Here, several possibilities arise. If resistance to different
drugs is conferred by different mutations, then the likeli-
hood of a patient having cancer cells with the multiple
mutations required for resistance to combination therapy
should be smaller than the likelihood of having the muta-
tion required for single agent resistance. Hence, combina-
tion therapy should result in improved response rates
relative to single agent therapy, and reduce the likelihood
of relapse. In a meta-analysis of single drugs versus
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combination therapies increased response, reduced
relapse, but had increased toxicity and only reduced over-
all mortality by modest amount (Carrick et al. 2005).
Similarly, a meta-analysis of single versus double or triple
drug therapies in nonsmall cell lung cancer found that
double drug therapies increased response rate, increased
1-year survival moderately, and increased median survival
time, but also increased toxicity (Delbaldo et al. 2004).
However, triple drug therapies increased response rates,
but did not signiﬁcantly improve 1-year survival or med-
ian survival time relative to single drug therapies (Del-
baldo et al. 2004). Thus, in combination therapy with
cytotoxins, there appears to be a trade-off between toxic-
ity and blocking therapeutic resistance.
Unlike multidrug cocktails used in the treatment of
other diseases (e.g. HAART therapy for HIV AIDS), com-
bination therapies have not transformed cancer into a
chronic disease. The reasons for this failure are unknown,
but may be due to single mutations that up-regulate
efﬂux pumps causing multi-drug resistance (Gottesman
et al. 2002). This notwithstanding, there is an urgent need
for more research into the evolution of chemotherapeutic
resistance and the design of multidrug therapies that act
synergistically to reduce the likelihood of relapse, and
thereby increase overall survival.
The Darwinian perspective suggests that interventions
that ameliorate progression or virulence without directly
killing neoplastic cells would delay the emergence of resis-
tance. Tamoxifen, and second generation selective estrogen
receptor modulators (SERMs) inhibit the proliferative
stimulation of breast cancer cells, generated by estrogen, by
blocking the estrogen receptor and hence, are cytostatic
rather than cytotoxic. Yet they have proven effective in
breast cancer therapy (Robertson 2004) and show
improved toxicity proﬁles compared to standard cytotox-
ins. The mechanism by which breast cancer tumors shrink
under SERM therapy is not fully understood (Dowsett
et al. 2001) but may involve both autophagy (Bursch et al.
1996) and apoptosis (Mandlekar and Kong 2001). The fact
that they reduce cancer cell proliferation should also slow
the rate at which novel resistance mutations arise.
Recent computational models suggest that hypothetical
benign cell boosters, which increase the ﬁtness of either
benign neoplastic clones or normal cells, may help to
drive the more dysplastic clones extinct and thereby delay
cancer progression. Since the drug would act to increase
ﬁtness, natural selection should lead to increased sensitiv-
ity rather than resistance (Maley et al. 2004c). Proton
pump inhibitors (PPIs) may be acting as a benign cell
booster in Barrett’s esophagus. If PPIs are being used to
suppress gastric acid reﬂux when the Barrett’s epithelium
is wounded, normal squamous epithelium grows to heal
the wound instead of neoplastic Barrett’s epithelium
(Paulson et al. 2006). A similar strategy might be
employed to boost the ﬁtness of chemosensitive cells, so
that they out-compete innately resistant cells before che-
motherapy is initiated (Maley et al. 2004c).
Implications of somatic evolution for drug
development
The somatic evolution theory of neoplastic progression
and acquired therapeutic resistance has several important
implications for drug development. The ﬁrst is that high
tumor cell toxicity does not invariably imply effective
treatment. Usually in cancer therapy the clinical objective
is to reduce the size of the tumor as quickly as possible
to achieve immediate clinical beneﬁt. This objective in
part underlies the twin concepts of a Maximum Tolerable
Dose (MTD) and the Therapeutic Index: the idea is to
design killing agents for which maximum cancer cell
mortality is achieved at a dose considerably lower than
the dose at which the therapy is toxic to the patient.
However, if heritable variation in susceptibility to the kill-
ing agent exists in the tumor cell population, high mor-
tality implies that only cells with very high resistance
escape killing. The result is a large difference in the aver-
age value of the trait (resistance) in those cells that are
killed, compared to those that survive, i.e. a large selec-
tion differential. A basic principle of quantitative genetics
holds that the rate of evolution of a trait is proportional
to the selective differential (Falconer and Mackay 1996)
such that, all else being equal, therapies causing high cell
mortality will increase the rate of evolution of resistance
compared to those inducing lower mortality.
The second point follows from the ﬁrst. As a conse-
quence of selection caused by therapeutic interventions,
the short-term therapeutic response may bear little rela-
tionship to the likelihood of effective long-term treat-
ment. The relationship between short- and long-term
therapeutic responses depends on the extent of heritable
phenotypic variation in cytotoxicity susceptibility: if no
such variability exists, there is no selection and dramatic
reductions in tumor burden can, at least in principle, be
achieved without signiﬁcant evolutionary response. If
such variation exists at the time therapy is initiated, or
arises soon thereafter, then dramatic initial reductions
imply strong selection, with a resulting dramatic rebound
effect. Thus while there are undoubtedly short-term clini-
cal beneﬁts associated with rapid and large reductions in
pathogen populations, the longer-term cost may well be
an accelerated rate of resistance evolution.
These considerations suggest that a key strategy for the
design of effective cancer therapeutics is to develop sys-
tematic methods for identifying drug targets for which
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2008a). Cancer cells thrive by altering their micro-
environment to make it more hospitable. The number of
neoplastic micro-environments, and the variation among
them, are expected to be much smaller than the number
of neoplastic cells, and the variation among them. By
targeting the cancer cell products that alter the micro-
environment, it is possible to halt or reverse tumor
growth without using cytotoxins to directly kill cancer
cells. This should, as noted above, be substantially less
prone to evolved resistance. Anti-angiogenic drugs are
well-established therapeutics that have been less prone to
acquired resistance than cytotoxic drugs (Boehm et al.
1997). It has been proposed that this advantage results
from the fact that anti-angiogenics target the microenvi-
ronment of tumor cells, rather than directly killing
individual cancer cells (Pepper 2008a).
Cancer stem cells
Although, we advocate for somatic evolution as the cen-
tral organizing theory of cancer biology, other ideas have
also been suggested as candidates for this role. Most
prominent among these is the idea of cancer stem cells.
Recently, cell surface markers have been identiﬁed that
are associated with the capacity for neoplastic cells to
engraft and propagate a neoplasm through serial xeno-
grafts into immune compromised mice (Hope et al. 2004;
Cho and Clarke 2008). These results have lead to the revi-
val of the ‘cancer stem cell’ hypothesis which posits that
only a small proportion of neoplastic cells are capable of
self-renewal and propagation.
Relapse can only occur if some self-renewing cells sur-
vive therapy. Do patients relapse because cancer stem cells
are inherently resistant to therapy (Costello et al. 2000;
Dean et al. 2005), or because therapy selected for a resis-
tant genetic or epigenetic variants in the cancer stem cell
pool? There is experimental evidence to support both
alternatives. The observation of clones with resistance
mutations and ampliﬁcations after therapy suggests that
in those cases, therapy resulted in positive Darwinian
selection on the cancer stem cells (Curt et al. 1983; Car-
man et al. 1984; Horns et al. 1984; Trent et al. 1984; Vi-
sakorpi et al. 1995; Taplin et al. 1999; Wang et al. 2004;
Kobayashi et al. 2005; Engelman et al. 2007; Shah et al.
2007). There is also experimental evidence that cancer
stem cells may have up-regulated efﬂux pumps (ATP-
binding cassette transporters) that protect the cancer stem
cells from cytotoxins (Dean et al. 2005). They also may
have active DNA repair and suppressed apoptosis
(Costello et al. 2000; Dean et al. 2005). If cancer stem
cells are relatively quiescent, then they should also be
more resistant to chemotherapies that target S-phase
compared to highly proliferative cancer cells (Dean et al.
2005). It is likely that both selection for resistance muta-
tions and a stem-like cell phenotype contribute to the
refractory nature of the disease.
Perhaps inevitably, the cancer stem cell hypothesis
remains controversial (Hill 2006; Polyak 2007). Certainly
from an evolutionary perspective, the presence of a large
majority of cancer cells with a putative limited potential
to proliferate is a surprise (McBride 2008). Cancer stem
cells, that expend a portion of their reproductive potential
on progeny with limited proliferative capacity, should be
at a competitive disadvantage relative to cancer stem cells
that always divide symmetrically to produce more cancer
stem cells. If the cancer stem cells are indeed rare (Adams
and Strasser 2008), one possibility is that there has not
been enough time in most neoplasms to select for an
increased frequency of cancer stem cells, an hypothesis
that could be tested by serial passage of neoplastic
cells through immune compromised mice. Indeed,
McBride (McBride 2008) hypothesizes that the putative
nonstem cells are really self-renewing cells that have
acquired a transient migratory, nonproliferative pheno-
type (McBride 2008). Another possibility is that cancer
nonstem cells may be altering the microenvironment of
the cancer stem cells so as to increase the ﬁtness of the
stem cells. In this way, selection may be acting on the
ensemble of cells.
The relative importance of stem versus nonstem com-
ponents in acquired resistance is still largely unknown.
Experiments that involve engrafting mouse cancer cells
into syngenic mice suggest that self-renewing cells may
not be rare (Adams and Strasser 2008), and a recent
study found a genetic lesion present in most of the breast
cancer nonstem cell component that was absent in the
(putative) stem cell compartment, suggesting that the
nonstem cells comprised an independent, self-renewing
clone (Shipitsin et al. 2007).
The cancer stem cell hypothesis is not a mutually
exclusive alternative to the somatic evolution theory of
acquired therapeutic resistance (Campbell and Polyak
2007; Visvader and Lindeman 2008). Moreover, as cur-
rently articulated, the cancer stem cell hypothesis does
not appear to offer an alternative explanation for neoplas-
tic progression, clonal expansions or tumor cell phyloge-
nies. In fact, the question of whether the entire neoplasm
or a minority of neoplastic cells is capable of self-renewal
is, at least in part, a question merely of the effective pop-
ulation size of the evolving cells in a neoplasm. But irre-
spective of whether the stem or nonstem cell component
is responsible for neoplasm self-renewal, there is broad
agreement that therapeutic targeting of the self-renewing
cells is crucial for effective disease management (Wang
2007).
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The somatic evolutionary theory of cancer progression
and acquired therapeutic resistance has profound impli-
cations for cancer therapy. It is, therefore, crucial that
further efforts be devoted to testing predictions of the
theory, especially in the clinical setting. For example, an
understanding of the selective effects of therapeutic
interventions requires that the genetic and epigenetic
structure of tumors be evaluated before, during and
after therapy. It is no accident that rapid progress in
understanding therapeutic resistance has been made in
hematopoietic malignancies where post-therapy samples
are easily acquired with minimally invasive procedures
(Shah et al. 2007). In solid tumors, clinicians are under-
standably reluctant to initiate further invasive proce-
dures to biopsy a neoplasm after the extended trauma
of cancer therapy has failed. Yet, longitudinal sampling
of neoplasms, during both progression and therapeutic
response, will be critical to our understanding of cancer
progression and the acquisition of resistance. This can
be done in hematopoietic neoplasms and some solid
tumors like Barrett’s esophagus and superﬁcial bladder
cancer where the standard of care is serial biopsy sur-
veillance. In other neoplasms, monitoring somatic evolu-
tion will depend on developing assays of cells shed
from the tissues in blood, urine, feces or sputum
samples.
Longitudinal evaluation will also be important in cell
culture or animal model studies. One underexploited
experimental design in animal models is serial biopsies of
a neoplasm as it develops and changes in response to
therapy. In contrast, most animal experiments in cancer
biology rely on sacriﬁcing the animal to take a tissue
sample and consequently do not generate longitudinal
data. Similarly, the long-term evolution of human cancer
cells could be tested by serially passaging the cells through
immune compromised mice, as is done in the routine
maintenance of some cell lines.
Most of evolutionary biology has been focused on
describing evolution. In order to prevent or cure cancer,
we will need to develop new methods to control or
manipulate the evolutionary process. It is our hope that
cancer biology may help to drive new evolutionary biol-
ogy research into the methods and theory for controlling
evolution. This is already a topic of intense interest in
infectious disease evolution (Ewald 1999; Levin et al.
1999; Rowe-Magnus and Mazel 2006; Pepper 2008a;
Stearns and Koella 2008).
As in other complex diseases, model systems are useful
for controlled experimentation, but often suffer from the
problem of limited extrapolation to clinical studies. Yet,
the possibility arises of supplementing controlled experi-
ments in more tractable model systems with observational
studies of somatic evolution in human neoplasms. Direct
observational studies of human neoplasms have provided
insights into how somatic evolution leads to cancer out-
comes (Maley et al. 2004a, 2006) and to therapeutic resis-
tance (Curt et al. 1983; Carman et al. 1984; Horns et al.
1984; Trent et al. 1984; Visakorpi et al. 1995; Taplin et al.
1999; Gorre et al. 2001; Roche-Lestienne and Pre-
udhomme 2003; Wang et al. 2004; Kobayashi et al. 2005;
Engelman et al. 2007; Shah et al. 2007). Longitudinal
sampling of some tissues is either noninvasive or already
routine (e.g. certain biopsies, pap smears, urine, blood,
feces, etc.). Detailed analysis of such samples will trans-
form the clinic into an environment for basic research on
premalignant neoplasms that provides critical information
for the elaboration and testing of hypotheses for human
carcinogenesis.
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